Policy Levers to Drive Change and Reform the Nation's Approach to Addiction

Regina LaBelle, JD

Director, Addiction and Public Policy Initiative, O'Neill Institute for National and Global Health Law

Director, Master of Science in Addiction Policy & Practice, Georgetown University Graduate School of Arts and Sciences

GEORGETOWN LAW

Professional & Financial Disclosures

I have no conflicts of interest to disclose.





The Addiction and Public Policy Initiative O'Neill Institute for National and Global Health Law at Georgetown University Law Center

Advancing a public health approach to substance use disorders through legal and policy strategies that promote evidence based treatment and support recovery.





GU

Addiction Policy and Practice



In today's policy environment, what effective, evidence-based policies can be implemented in light of increasing rates of overdose death and increasing availability of illicitly manufactured fentanyl? Significant barriers remain to reforming the nation's current approaches to substance use disorder. We'll discuss how to use the various policy levers at our disposal to drive reform, including litigation proceeds.



Current State

Based on data available for analysis on: January 1, 2023







Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: August 2021 to August 2022



Current State

Figure 4. Age-adjusted rate of drug overdose deaths involving opioids, by type of opioid: United States, 2001–2021



Significant increasing trend from 2001 through 2021 with different rates of change over time, p < 0.05.

SOURCE: National Center for Health Statistics, National Vital Statistics System, Mortality File

X60-X64, X85, and Y10-Y14. Among these deaths, the following ICD-10 multiple cause-of-death codes indicate the drug type(s) involved: T40.0-T40.4, T40.6, any opioid; T40.1, heroin; T40.2, natural and semisynthetic opioids; T40.3, methadone; and T40.4, synthetic opioids other than methadone. Age-adjusted death rates were calculated using the direct method and the 2000 U.S. standard population. Deaths involving more than one opioid category (a death involving both methadone and a natural or semisynthetic opioid, for example) were counted in both categories. The percentage of drug overdose deaths that identified the specific drugs involved varied by year, ranging from 75% to 79% from 2000 through 2013 and increasing from 81% in 2014 to 95% in 2021. Access data table for Figure 4 at: https://www.cdc.gov/nchs/data/databriefs/db457-tables.pdf#4.

Significant increasing trend from 2001 through 2010, then stable trend from 2010 through 2021, p < 0.05.


Significant increasing trend from 2001 through 2015 with different rates of change over time, stable trend from 2015 through 2019, then significant decreasing trend from 2019 through 2021, p < 0.05.

Significant increasing trend from 2001 through 2006 with different rates of change over time, significant decreasing trend from 2006 through 2019, then stable trend from 2019 through 2021, p < 0.05.

NOTES: Drug overdose deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause-of-death codes X40-X44,

National Trends

Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: August 2021 to August 2022



Select predicted or reported number of deaths

Predicted

O Reported

Percent Change for United States


3.3



Racial Disparities

Figure 2

Drug Overdose Deaths Per 100,000, by Race/Ethnicity



NOTES: Persons of Hispanic origin may be of any race but are categorized as Hispanic; other groups are non-Hispanic. AIAN refers to American Indian and Alaska Native people. NHOPI refers to Native Hawaiian or Pacific Islanders.


SOURCE: Estimates for 2018 are from CDC National Center for Health Statistics. Multiple Cause of Death 2018-2019 on CDC WONDER Online Database, from: https://wonder.cdc.gov/mcd-icd10-expanded.html. Estimates for 2019 and 2020 are based on provisional CDC, National Vital Statistics System data, from: https://www.cdc.gov/nchs/data/health-policy/Provisional-Drug-Overdose-Deaths-Quarter-Demographic-Q32020.pdf. Population estimates from Census Bureau Monthly Population Estimates.







Past Year Substance Use Disorder (SUD): Among People Aged 12 or Older; 2021



Note: The estimated numbers of people with substance use disorders are not mutually exclusive because people could have use disorders for more than one substance.

¹ Includes data from all past year users of marijuana, cocaine, heroin, hallucinogens, inhalants, methamphetamine, and prescription psychotherapeutic drugs (i.e., pain relievers, tranquilizers, stimulants, or sedatives).

² Includes data from all past year users of the specific prescription drug.

U.S. Students Reporting Any Past-Year Illicit Drug Use*




*Illicit drug use in this survey was defined as use of marijuana, LSD, other hallucinogens, crack, other cocaine, or heroin; or any use of narcotics other than heroin, amphetamines, sedatives (barbiturates), or tranquilizers not under a doctor's orders.

Source: 2021 Monitoring the Future Survey



Adolescent (14-18) Overdose Deaths




Drug overdose rates per 100 000 adolescents are shown by (A) substance involved and (B) race and ethnicity. The year 2021 refers to January to June 2021, and rates have been annualized. The vertical dashed lines delineate the prepandemic and pandemic periods of observed data.

Research Letter

April 12, 2022

Trends in Drug Overdose Deaths Among US Adolescents, January 2010 to June 2021 Joseph Friedman, MPH¹; Morgan Godvin, BA²; Chelsea L. Shover, PhD³; et al

Number of Pills Containing Fentanyl Seized by Law Enforcement in the United States, 2018 – 2021



Estimates based on data reported by the Office of National Drug Control Policy's High Intensity Drug Trafficking Areas program

Reference: JJ Palamar, et al. Drug and Alcohol Dependence. DOI: 10.1016/j.drugalcdep.2022.109398 (2022)





Research into Policy

FIRST OPINION

Unlocking federal funding for fentanyl test strips will save lives

By Regina LaBelle, Tom Coderre and Rochelle Walensky May 4, 2021








Mobile Medication Units Help Fill Gaps in Opioid Use Disorder Treatment

New Jersey state official reflects on how services help reach people in need

ARTICLE November 22, 2021 Read time: 5 min
Projects: Substance Use Prevention and Treatment

P'NEILL
INSTITUTE
FOR NATIONAL & GLOBAL HEALTH LAW
GEORGETOWN LAW

The American Rescue Plan Act of 2021



2022 Policy Changes

- Mainstreaming Addiction Treatment Act
- Medication Access and Training Expansion
- Codifies Mobile Treatment Units
- Extends Tele-health flexibilities for Medicare
- HHS must consider need for "Safe Harbor" provision (CMS)
- States can continue Medicaid for pre-trial juveniles during incarceration
- Extended class fentanyl scheduling until 12/24



2022 Methadone Proposed Rule

- Revises:
 - Definition of "qualifying practitioner"
 - Admission criteria
- Expands access to evidence-based practices such as split dosing, telehealth and harm reduction activities.
- Revises the provision containing the criteria for take home doses of methadone.
- Allows for greater flexibility for plans of care that promote recovery.
- Promotes the chronic disease model of management, while removing barriers to providing individualized care.
 - This is designed to encourage patient engagement and to reduce the need for individuals to attend an OTP each day to receive medication.








Activist Tourism:

Engaging in efforts to reform policies in a short-term or superficial way. Resulting in short-term gratification and few long-term results. Emphasizing "should" rather than "how".





Moving from Should to How





BIGIDEAS

MAXIMIZING THE IMPACT OF OPIOID LITIGATION TO ADDRESS THE OVERDOSE EPIDEMIC

SYSTEMS OF OVERSIGHT AND ACCOUNTABILITY CAN ENSURE THAT OPIOID SETTLEMENT FUNDS ARE USED TO ADVANCE PUBLIC HEALTH STRATEGIES.



Key Principles

- 1. Intentional collaboration leads to actionable policy
- 2. The needs of the community must be reflected in the distribution of proceeds
- 3. Litigation proceeds should supplement not supplant existing funding
- 4. Oversight and continuous feedback are key
- 5. Maximize and coordinate other sources of funding to create a comprehensive plan to address substance use disorders

Legislative Strategies

The Model Opioid Litigation Proceeds Act was developed by the O'Neill Institute for National and Global Health Law, the Legislative Analysis and Public Policy Association, the Center for U.S. Policy, and Brown & Weinraub, PLLC with support by the White House Office of National Drug Control Policy. This Act will guide state legislatures in ensuring that opioid litigation settlement funds are directed to addressing addiction and the overdose epidemic in impacted communities and with public accountability.

Opioid Litigation Proceeds Act

- Framework for new or amended legislation
- Key Elements: Dedicated fund and diverse council with knowledge and expertise in the field
- Includes "evidence-informed" allows for innovation

State and federal legislation, when coupled with carefully crafted settlement agreements, can create guardrails for the use of opioid litigation proceeds.



The Way Forward

- Providing Quality Treatment
- Build the Workforce
- No one is incarcerated for drug use alone
- Child welfare = Family welfare
- MOUD is accessible in corrections and reentry
- The continuum of care includes harm reduction
- Prevention is emphasized and includes the social determinants of addiction.
- Funding sources are integrated to improve outcomes and efficiency

Acknowledgment of the lives lost













Maximizing the Impact of Opioid Litigation Settlements⁸

The Model Opioid Litigation Proceeds Act

Project Page:

oneill.law.georgetown.edu/projects/maximizing-the-impact-of-opioid-litigation-settlements/

Model Act:

legislativeanalysis.org/model-opioid-litigation-proceeds-act/

Summit:

oneill.law.georgetown.edu/events/opioid-litigation-summit/



CONTACT

The O'Neill Institute for National and Global Health Law

Georgetown University Law Center

600 New Jersey Avenue, NW Washington, DC 20001

Web: https://oneill.law.georgetown.edu/

Regina LaBelle, JD

Email: Regina.LaBelle@georgetown.edu

Twitter: @Reginalabelle

@ADPP_Georgetown

